AR021137A1 - Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados. - Google Patents

Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados.

Info

Publication number
AR021137A1
AR021137A1 ARP990105681A ARP990105681A AR021137A1 AR 021137 A1 AR021137 A1 AR 021137A1 AR P990105681 A ARP990105681 A AR P990105681A AR P990105681 A ARP990105681 A AR P990105681A AR 021137 A1 AR021137 A1 AR 021137A1
Authority
AR
Argentina
Prior art keywords
alkyl
prepare
substituted
derivatives
procedure
Prior art date
Application number
ARP990105681A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR021137A1 publication Critical patent/AR021137A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Abstract

Esta invencion se refiere al uso de compuesto que tienen la formula (1) a los N-oxidos, a las sales de adicion farmacéuticamente aceptables, las aminascuaternarias y sus formas estereoquímicamente isoméricas en las cuales -a1=a2-a3=a4- forman unfeni lo, piridinilo, pirimidinilo, piridazinilo opirazinilo con el grupo vinilo adherido; n es 0 a 4 y donde es posible 5; R1 es hidrogeno, arilo; formilo; alquilcarbonilo C1-6; alquilo C1-6;alquiloxicarbonilo C1-6; alquilo C1-6 substituido oalquiloxi C1 -6; alquilcarbonilo C1-6 substituido; cada R2 independientemente es hidroxi, halo, alquilo C1-6opcionalmente substituido; alquilo C1-6, alquenilo C2-6 substituido o alquinilo C2-6, cicloalquilo C3-7, alquiloxi C1-6; alquiloxicarboniloC1-6; carboxilo ,ciano, nitro, amino, mono o di(alquilo C1-6) amino, polihalometilo, polihalometiloxi, polihalometiltio, -S(=O)pR4, -NH-S(=O)NHNH2; -NHC(=O)R4, -C(=NH)R4 o unanillo heterocíclico de 5 miembros; p es 1 o 2; L es alquilo C1-10,substituido, alquenilo C 2-10, alquinilo C2-10, cicloalquilo C3-7:0 L es -X-R3 donde R3 esfenilo, piridinilo, pirimidinilo, pirazinilo o piridazinilo opcionalmente substituido, X es -NR1-, -NH-NH-, -N=N-, -O-. -C(=O)-, -CHOH-, -S-, -S(=O)- o -S(=O)2- ; arilo es fenilo substit uido; para la manufactura de un medicamento para el tratamiento de individuos que sufren de infeccion causada por virus de HIV (Virusde Inmunodeficiencia Humana).
ARP990105681A 1998-11-10 1999-11-09 Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados. AR021137A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24

Publications (1)

Publication Number Publication Date
AR021137A1 true AR021137A1 (es) 2002-06-12

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105681A AR021137A1 (es) 1998-11-10 1999-11-09 Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados.

Country Status (35)

Country Link
US (2) US6638932B1 (es)
EP (1) EP1129079B1 (es)
JP (1) JP2002529457A (es)
KR (1) KR100620402B1 (es)
CN (1) CN1207290C (es)
AP (1) AP1636A (es)
AR (1) AR021137A1 (es)
AT (1) ATE315031T1 (es)
AU (1) AU764472B2 (es)
BG (1) BG65160B1 (es)
BR (1) BR9915176A (es)
CA (1) CA2351203C (es)
CY (1) CY1105596T1 (es)
CZ (1) CZ20011532A3 (es)
DE (1) DE69929354T2 (es)
DK (1) DK1129079T3 (es)
EA (1) EA004501B1 (es)
EE (1) EE200100253A (es)
ES (1) ES2257081T3 (es)
HK (1) HK1038232A1 (es)
HR (1) HRP20010310A2 (es)
HU (1) HUP0104395A3 (es)
ID (1) ID28545A (es)
IL (2) IL143024A0 (es)
MY (1) MY126781A (es)
NO (1) NO319788B1 (es)
NZ (1) NZ510919A (es)
OA (1) OA11675A (es)
PL (1) PL196523B1 (es)
PT (1) PT1129079E (es)
SI (1) SI1129079T1 (es)
SK (1) SK6022001A3 (es)
TR (1) TR200101319T2 (es)
TW (1) TW541305B (es)
WO (1) WO2000027828A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011532A3 (cs) * 1998-11-10 2001-10-17 Janssen Pharmaceutica N. V. 2,4-Disubstituované triazinové deriváty
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
EP1597242B1 (en) * 2003-02-07 2008-07-23 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
RU2401833C2 (ru) 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (es) * 1970-05-13 1974-07-18
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) * 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
CZ20011532A3 (cs) * 1998-11-10 2001-10-17 Janssen Pharmaceutica N. V. 2,4-Disubstituované triazinové deriváty

Also Published As

Publication number Publication date
DK1129079T3 (da) 2006-05-15
AU764472B2 (en) 2003-08-21
AU1046200A (en) 2000-05-29
WO2000027828A2 (en) 2000-05-18
EA200100534A1 (ru) 2001-10-22
BG105419A (en) 2001-11-30
KR100620402B1 (ko) 2006-09-13
NO20011934D0 (no) 2001-04-19
NO20011934L (no) 2001-04-19
HRP20010310A2 (en) 2002-06-30
SI1129079T1 (sl) 2006-06-30
CZ20011532A3 (cs) 2001-10-17
HUP0104395A2 (hu) 2002-04-29
CY1105596T1 (el) 2010-07-28
CN1325387A (zh) 2001-12-05
EP1129079B1 (en) 2006-01-04
AP1636A (en) 2006-07-17
HK1038232A1 (en) 2002-03-08
JP2002529457A (ja) 2002-09-10
CN1207290C (zh) 2005-06-22
EE200100253A (et) 2002-12-16
TR200101319T2 (tr) 2001-10-22
KR20010075234A (ko) 2001-08-09
OA11675A (en) 2005-01-12
TW541305B (en) 2003-07-11
IL143024A0 (en) 2002-04-21
DE69929354D1 (de) 2006-03-30
ID28545A (id) 2001-05-31
MY126781A (en) 2006-10-31
EP1129079A2 (en) 2001-09-05
HUP0104395A3 (en) 2003-02-28
EA004501B1 (ru) 2004-04-29
PL196523B1 (pl) 2008-01-31
BG65160B1 (bg) 2007-04-30
US20050277641A1 (en) 2005-12-15
WO2000027828A3 (en) 2000-09-21
NO319788B1 (no) 2005-09-12
SK6022001A3 (en) 2002-01-07
DE69929354T2 (de) 2006-09-14
ES2257081T3 (es) 2006-07-16
US7015221B2 (en) 2006-03-21
BR9915176A (pt) 2001-08-14
IL143024A (en) 2006-06-11
NZ510919A (en) 2003-11-28
PT1129079E (pt) 2006-05-31
PL348145A1 (en) 2002-05-06
ATE315031T1 (de) 2006-02-15
CA2351203C (en) 2009-03-24
US6638932B1 (en) 2003-10-28
CA2351203A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR122015023612B8 (pt) compostos derivados de pirimidina, seu uso, composição farmacêutica e produto
ES2193664T3 (es) Pirimidinas inhibidoras de la replicacion del vih.
BRPI0407741B8 (pt) pirimidinas e triazinas de inibição de replicação de hiv
CY1110979T1 (el) Παραγωγα κιναζολινης ως αναστολεις αγγειογενεσης και ενδιαμεσες ενωσεις αυτων
EA200400615A1 (ru) Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
EA200400616A1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR038864A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
DK0730594T3 (da) 9-hydroxy-pyrido{1,2-a}pyrimidin-4-on-ether-derivater
AR039540A1 (es) Compuestos microbicidas con contenido de pirimidina o triazina
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
AR008864A1 (es) DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
AR021137A1 (es) Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados.
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
AR002025A1 (es) Derivados de 4-(1h-indol-1-il)-1-piperidinilo, su uso y un procedimiento para su preparacion, una composicion farmaceutica que los contiene, unprocedimiento para la preparacion de dicha composicion farmaceutica.
ECSP034619A (es) Derivados de pirimidina
AR017146A1 (es) Compuestos de 1-(fenil-sustituido)-5-(4-metilsulfonilfenil)pirazol; procedimiento para prepararlos, las composiciones farmaceuticas que los contienen,los agentes inhibidores de la cox-ii que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos.
AR016594A1 (es) DERIVADOS DE 3,4,5,7-TETRAHIDRO-PIRROLO[3',4':4,5]TIENO[2,3-d]PIRIMIDINA 3-SUSTITUIDOS Y SU USO PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS
UY27568A1 (es) Forma de fármaco cristalina
PA8545601A1 (es) Derivados de 4-aminopirimidina
BR9811499A (pt) "derivados da 6-azauracila como inibidores da il-5"
PT1068200E (pt) Antifungicos 1,3-dioxolano 2,4,4-tir-substituidos

Legal Events

Date Code Title Description
FG Grant, registration